12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Perifosine: Phase I data

Perifosine has Orphan Drug designation in the U.S. to treat neuroblastoma. In May, Aeterna and Keryx Biopharmaceuticals Inc. (NASDAQ:KERX, New York, N.Y.) mutually terminated a deal that gave Keryx North American rights to perifosine. Keryx is still eligible for low single-digit royalties on sales of perifosine in North America. Aeterna said it will continue a Phase III trial of perifosine in multiple myeloma (MM) (see BioCentury, May 14). Yakult has rights to perifosine in Japan, while Handok has rights in South Korea. Perifosine...

Read the full 401 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >